TAVLESSE 100 mg, film-coated tablet 60 tablets
Active ingredients: Fostamatinib, Fostamatinib disodium hexahydrate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TAVLESSE 100 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 comprimé(s)
- Marketing authorisation holder
- INSTITUTO GRIFOLS
- Reimbursement according to BDPM
- 15 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Oct 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62637153CIP73020780CIP133400930207802Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FOSTAMATINIB DISODIQUE HEXAHYDRATÉcomprimé | 126,2 mg · un comprimé | SA |
| FOSTAMATINIBcomprimé | 100 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.